A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas

被引：0
|
作者：
Stéphane Goutagny
Marco Giovannini
Michel Kalamarides
机构：
[1] Assistance Publique Hôpitaux de Paris,Neurochirurgie
[2] Hôpital Beaujon,undefined
[3] Hôpital Pitié Salpêtrière,undefined
[4] Assistance Publique Hôpitaux de Paris,undefined
[5] University of California Los Angeles,undefined
来源：
Journal of Neuro-Oncology | 2017年 / 133卷
关键词：
Bevacizumab; Meningioma; Everolimus; Rebound Effect; Vestibular Schwannoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：443 / 445
页数：2
相关论文
共 50 条
  • [41] Phase 2 Study of Everolimus Monotherapy in Patients With Nonfunctioning Neuroendocrine Tumors or Pheochromocytomas/Paragangliomas
    Oh, Do-Youn
    Kim, Tae-Won
    Park, Young Suk
    Shin, Sang Joon
    Shin, Seong Hoon
    Song, Eun-Kee
    Lee, Hyo Jin
    Lee, Kewn-Wook
    Bang, Yung-Jue
    CANCER, 2012, 118 (24) : 6162 - 6170
  • [42] RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma
    Ravaud, A.
    Barrios, C. H.
    Alekseev, B.
    Tay, M. -H.
    Agarwala, S. S.
    Yalcin, S.
    Lin, C. -C.
    Roman, L.
    Shkolnik, M.
    Anak, O.
    Gogov, S.
    Pelov, D.
    Louveau, A. -L.
    Melichar, B.
    ANNALS OF ONCOLOGY, 2015, 26 (07) : 1378 - 1384
  • [43] A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours
    Fazio, Nicola
    Buzzoni, Roberto
    Baudin, Eric
    Antonuzzo, Lorenzo
    Hubner, Richard A.
    Lahner, Harald
    De Herder, Wouter W.
    Raderer, Markus
    Teule, Alexandre
    Capdevila, Jaume
    Libutti, Steven K.
    Kulke, Matthew H.
    Shah, Manisha
    Dey, Debarshi
    Turri, Sabine
    Aimone, Paola
    Massacesi, Cristian
    Verslype, Chris
    ANTICANCER RESEARCH, 2016, 36 (02) : 713 - 719
  • [44] Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4)
    Motzer, R. J.
    Alyasova, A.
    Ye, D.
    Karpenko, A.
    Li, H.
    Alekseev, B.
    Xie, L.
    Kurteva, G.
    Kowalyszyn, R.
    Karyakin, O.
    Neron, Y.
    Cosgriff, T.
    Collins, L.
    Brechenmacher, T.
    Lin, C.
    Morgan, L.
    Yang, L.
    ANNALS OF ONCOLOGY, 2016, 27 (03) : 441 - 448
  • [45] Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study
    Capdevila, Jaume
    Teule, Alexandre
    Barriuso, Jorge
    Castellano, Daniel
    Lopez, Carlos
    Luis Manzano, Jose
    Alonso, Vicente
    Garcia-Carbonero, Rocio
    Dotor, Emma
    Matos, Ignacio
    Custodio, Ana
    Casanovas, Oriol
    Salazar, Ramon
    ONCOLOGIST, 2019, 24 (01) : 38 - 46
  • [46] Phase I/II Study of a Vascular Endothelial Growth Factor Receptor Vaccine in Patients With NF2-Related Schwannomatosis
    Tamura, Ryota
    Yamanobe, Yoshiharu
    Fujioka, Masato
    Morimoto, Yukina
    Fukumura, Mariko
    Nakaya, Masato
    Oishi, Yumiko
    Sato, Mizuto
    Ueda, Ryo
    Fujiwara, Hirokazu
    Hikichi, Tetsuro
    Noji, Shinobu
    Oishi, Naoki
    Ozawa, Hiroyuki
    Ogawa, Kaoru
    Kawakami, Yutaka
    Ohira, Takayuki
    Yoshida, Kazunari
    Toda, Masahiro
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (21) : 2578 - 2587
  • [47] The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study
    Tan, Peter
    Tiong, Ing Soo
    Fleming, Shaun
    Pomilio, Giovanna
    Cummings, Nik
    Droogleever, Mark
    McManus, Julie
    Schwarer, Anthony
    Catalano, John
    Patil, Sushrut
    Avery, Sharon
    Spencer, Andrew
    Wei, Andrew
    ONCOTARGET, 2017, 8 (32) : 52269 - 52280
  • [48] Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum
    D H Yoon
    M-H Ryu
    Y S Park
    H J Lee
    C Lee
    B-Y Ryoo
    J-L Lee
    H-M Chang
    T W Kim
    Y-K Kang
    British Journal of Cancer, 2012, 106 : 1039 - 1044
  • [49] A Phase II Study of Everolimus in Patients with Unresectable Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Contained Chemotherapy
    Morizane, C.
    Okuyama, H.
    Ikeda, M.
    Furuse, J.
    Furukawa, M.
    Ueno, M.
    Kojima, M.
    Yamanaka, T.
    Okusaka, T.
    NEUROENDOCRINOLOGY, 2019, 108 : 175 - 175
  • [50] Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum
    Yoon, D. H.
    Ryu, M-H
    Park, Y. S.
    Lee, H. J.
    Lee, C.
    Ryoo, B-Y
    Lee, J-L
    Chang, H-M
    Kim, T. W.
    Kang, Y-K
    BRITISH JOURNAL OF CANCER, 2012, 106 (06) : 1039 - 1044
12345